focus -WSS

focus

author：comprehensive 2025-10-02 20:53:10 - browse：9886

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Did you have Obamacare on your GOP debate bingo card?

hotspot

WSS

Doctors increasingly discourage vaping amid mounting health concerns

Adidas to release second batch of Yeezy sneakers after breakup with Ye

Doctors increasingly discourage vaping amid mounting health concerns

Russian and Belarusian players banned from a women's tennis tournament in Prague

How one patient went off dialysis — and others can too

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

explore

focus

focus

Tori Bowie and the unacceptable rates of Black maternal death

FDA seeks to regulate lab

At least 13 dead in Texas as scorching temps continue

Trump PAC spent more than $40M on legal bills this year as his charges mount: Sources

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

'Weather

Anesthesiologist group: stop taking Ozempic before surgery

Russian and Belarusian players banned from a women's tennis tournament in Prague

hotspot

Address the ethical violations that led to 'Three Identical Strangers'

Campaign finance charge dropped from case against Sam Bankman

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

FDA seeks to regulate lab

Menendez indictment could see pharma lose a key ally

WHO recommends dropping component of many flu vaccines

focus

hotspot

focus

explore